

Oklahoma Health Care Authority
Drug Utilization Review Board
(DUR Board)
Meeting – February 8, 2012 @ 6:00 p.m.

Oklahoma Health Care Authority
2401 N.W. 23rd Street, Suite 1-A
Oklahoma City, Oklahoma 73107
Ponca Room (North Entrance)

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
 - A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. January 11, 2011 DUR Minutes – Vote
 - B. January 12, 2011 DUR Recommendation Memorandum

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

4. **Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
 - A. Retrospective Drug Utilization Review for October 2011
 - B. Medication Coverage Activity Audit for January 2012
 - C. Pharmacy Help Desk Activity Audit for January 2012

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

5. **Action Item – Vote to Prior Authorize Select Prenatal Vitamins– See Appendix C.**
 - A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

6. **Action Item – Vote to Prior Authorize Soliris[®] – See Appendix D.**
 - A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

7. **Action Item – Vote to Prior Authorize Onfi[™] – See Appendix E.**
 - A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

8. **Action Item – Annual Review of Erythropoietin Stimulating Agents – See Appendix F.**
- A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorization Review
 - D. Market News and Updates
 - E. COP Recommendations

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

9. **Action Item – Annual Review of Narcotic Analgesics and 30 Day Notice to Prior Authorize Abstral[®], Lazanda[®], Nucynta[®] ER, and Oxecta[®] – See Appendix G.**
- A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorization Review
 - D. Hydrocodone Utilization
 - E. Suboxone[®] and Subutex[®] Review
 - F. Market News and Updates
 - G. COP Recommendations

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

10. **30 Day Notice to Prior Authorize Xgeva[®] – See Appendix H.**
- A. Product Summary
 - B. COP Recommendations

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

11. **30 Day Notice to Prior Authorize Makena[™] – See Appendix I.**
- A. Product Summary
 - B. COP Recommendations
 - C. Product Details

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

12. **Action Item – Questions Regarding Annual Review of Mozobil[®], Nplate[®], Arcalyst[®], and Ilaris[®] – See Appendix J.**
- A. Current Authorization Criteria
 - B. Utilization Review
 - C. Market News and Updates
 - D. COP Recommendations

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman

13. **FDA and DEA Updates – See Appendix K.**
14. **Future Business**
- A. Annual Review Qutenza[®]
 - B. Annual Review of Miscellaneous Special Formulation Anti-Infectives
 - C. New Product Reviews
 - D. Medical Product Reviews
15. **Adjournment**